Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Briumvi. Always confirm against the full prescribing information.
100 interactions
Abatacept
The risk or severity of infection can be increased when Ublituximab is combined with Abatacept.
Level 1 evidence
Adalimumab
The risk or severity of infection can be increased when Ublituximab is combined with Adalimumab.
Level 1 evidence
Alclometasone
The risk or severity of infection can be increased when Ublituximab is combined with Alclometasone.
Level 1 evidence
Aldesleukin
The risk or severity of infection can be increased when Ublituximab is combined with Aldesleukin.
Level 1 evidence
Alemtuzumab
The risk or severity of infection can be increased when Ublituximab is combined with Alemtuzumab.
Level 1 evidence
Amcinonide
The risk or severity of infection can be increased when Ublituximab is combined with Amcinonide.
Level 1 evidence
Anakinra
The risk or severity of infection can be increased when Ublituximab is combined with Anakinra.
Level 1 evidence
Anifrolumab
The risk or severity of infection can be increased when Ublituximab is combined with Anifrolumab.
Level 1 evidence
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ublituximab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of infection can be increased when Ublituximab is combined with Antilymphocyte immunoglobulin (horse).
Level 1 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of infection can be increased when Ublituximab is combined with Antithymocyte immunoglobulin (rabbit).
Level 1 evidence
Apremilast
The risk or severity of infection can be increased when Ublituximab is combined with Apremilast.
Level 1 evidence
Enter your NPI to unlock 4 major interactions for Briumvi
Briumvi (Ublituximab) has 393 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Briumvi (Ublituximab) has 12 major, 262 moderate, and 119 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Briumvi. Always confirm against the full prescribing information.